Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
NCT05007418
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This is a study for people who have a type of cancer called multiple myeloma that is not getting better with normal treatments. They will be given a drug called STI-1492 through a vein to see if it helps them. The study is in the early stages and is testing different doses of the drug.
This is a study for people who have a type of cancer called multiple myeloma that is not getting better with normal treatments. They will be given a drug called STI-1492 through a vein to see if it helps them. The study is in the early stages and is testing different doses of the drug.
Third Opinion AI Generated Synopsis
Trial Summary
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
